Literature DB >> 471580

Transient partial hGH deficiency in prepubertal children with delay of growth.

M Gourmelen, M T Pham-Huu-Trung, F Girard.   

Abstract

UNLABELLED: The hGH response to an ornithin or an insulin test was measured in 105 children from 11-18 yr old with delay of growth more than 2 SD. Besides 74 subjects with normal values and 7 with complete lack of response, 24 subjects exhibited a partial rise of GH. Most of the latter had decreasing growth rate and no sign of puberty. Out of 15 assessed for GH function after onset of puberty, 14 showed a normal response accompanying a markedly increased growth velocity. Four other subjects with partial response who were receiving sexual hormones for 48 hr before the second test showed a normal response also. An exogenous hGH treatment administered in two of these patients resulted in a marked and sustained growth increase far before entering puberty. SPECULATION: The findings that plasma GH responses to stimulation tests is reduced in some children with decreasing growth rate before puberty and return to normal after onset of sexual development, would suggest a transient and functional defect in growth hormone secretion and the physiologic role of sexual hormones on GH release mechanism at that period of life.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 471580     DOI: 10.1203/00006450-197904000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  21 in total

1.  The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.

Authors:  S Loche; C Pintor; P Cambiaso; A Lampis; D Carta; R Corda; M Cappa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

2.  Short Stature in Childhood and Adolescence: Part 1: Medical management.

Authors:  F N Schnell; J R Bannard
Journal:  Can Fam Physician       Date:  1991-10       Impact factor: 3.275

3.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  Transient growth deceleration in normal short children. A potential source of bias in growth studies.

Authors:  C Polychronakos; H Abu-Srair; H J Guyda
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

5.  Growth hormone insufficiency in a girl with the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  A Franzese; G Valerio; S Di Maio; M P Iannucci; A Bloise; A Tenore
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 6.  Stunted growth with more or less normal appearance.

Authors:  J R Bierich; H Enders; U Heinrich; R Huenges; M B Ranke; D Schoenberg
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

7.  Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine.

Authors:  F Orio; N Padovano; L Cinquanta; A Colao; B Merola; S Longobardi; E Rossi; V Esposito; F Orio; G Lombardi
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

Review 8.  Clinical practice. Short stature in childhood--challenges and choices.

Authors:  David B Allen; Leona Cuttler
Journal:  N Engl J Med       Date:  2013-03-28       Impact factor: 91.245

9.  Growth-hormone releasing factor and clonidine in children with constitutional growth delay. Evidence for defective pituitary growth hormone reserve.

Authors:  C Pintor; R Puggioni; V Fanni; S G Cella; A Villa; V Locatelli; E E Müller
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

10.  Occurrence of four types of growth hormone-related dwarfism in Israeli communities.

Authors:  A Adam; Z Josefsberg; A Pertzelan; Z Zadik; J M Chemke; Z Laron
Journal:  Eur J Pediatr       Date:  1981-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.